CJC-1295 + Ipamorelin + GHRP-2

Overview

This product is a triple growth-hormone secretagogue blend that combines three peptides in a single 9 mg lyophilized vial: CJC-1295 without DAC (also known as Mod GRF 1-29), ipamorelin, and GHRP-2. Each belongs to the broad class of growth-hormone secretagogues, but they are drawn from two distinct pharmacological families.

CJC-1295 without DAC is a synthetic analog of growth-hormone-releasing hormone (GHRH). Ipamorelin and GHRP-2 are ghrelin mimetics — they act on the growth-hormone secretagogue receptor rather than the GHRH receptor. The rationale for packaging them together is that a GHRH analog and a ghrelin mimetic are commonly studied as complementary partners, each engaging a different lever on the pituitary.

Most of the underlying evidence comes from studies of the individual components rather than of this specific three-peptide combination. Human clinical data on the blend itself is limited, and none of these peptides is approved by a major regulator for therapeutic use. They are sold for research purposes only.

How it works

The pituitary’s release of growth hormone is regulated by two opposing signals: GHRH, which stimulates release, and somatostatin, which suppresses it. CJC-1295 acts as a GHRH analog to drive the stimulatory arm, while ipamorelin and GHRP-2 act on the ghrelin/secretagogue-receptor pathway. In studies of GHRH analogs paired with ghrelin mimetics, the two mechanisms have been reported to combine for a larger growth-hormone pulse than either produces alone, which is the basis for the “synergy” often described for blends like this one.

Ipamorelin is notable in the research literature for its selectivity: it has been reported to stimulate growth-hormone release without meaningfully raising cortisol, prolactin, or ACTH. GHRP-2 is a more potent secretagogue that has additionally been observed to increase appetite in study settings. The precise combined effect and safety profile of all three together in humans is not well established.

Reported benefits

• Amplified, more synergistic growth-hormone release than single-peptide approaches (based on studies of GHRH-analog plus ghrelin-mimetic pairings)
• Interest in supporting recovery, body composition, and sleep quality, which are commonly cited goals for growth-hormone secretagogues
• Selective growth-hormone stimulation from the ipamorelin component, reported with minimal effect on cortisol and prolactin

These are reported and studied effects, not guaranteed outcomes, and much of the evidence is preclinical or drawn from the individual peptides rather than the blend.

Considerations & side effects

Because robust human trials of this specific combination are lacking, its long-term safety profile is not well characterized. Reported side effects for the component peptides are generally mild and include injection-site irritation, flushing, headache, water retention, and transient changes in appetite — the last most associated with GHRP-2. Growth-hormone secretagogues can also affect blood-sugar handling, which is a relevant consideration for anyone monitoring glucose.

Product purity and the exact ratio of the three peptides vary in the research-chemical market, and a combination product concentrates several variables into one vial. This information is educational only and is not a substitute for evaluation and treatment by a qualified clinician.